
Results
11
Companies which are more than 50% undervalued based on analyst price target.
11 companies
Daiichi Sankyo Company
Market Cap: JP¥4.7t
Manufactures and sells pharmaceutical products in Japan and internationally.
4568
JP¥2,647.50
7D
4.4%
1Y
-17.9%
GNI Group
Market Cap: JP¥159.4b
Engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States.
2160
JP¥2,841.00
7D
12.9%
1Y
-8.8%
PeptiDream
Market Cap: JP¥134.9b
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
4587
JP¥1,026.00
7D
0.05%
1Y
-34.1%
Nxera Pharma
Market Cap: JP¥88.9b
Operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.
4565
JP¥967.00
7D
1.4%
1Y
10.4%
SanBio
Market Cap: JP¥78.8b
Engages in the development, production, and sale of regenerative cell medicines for the central nervous system.
4592
JP¥1,072.00
7D
16.6%
1Y
-50.6%
Heartseed
Market Cap: JP¥36.2b
Develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure.
219A
JP¥1,632.00
7D
6.3%
1Y
-41.2%
Healios K.K
Market Cap: JP¥34.4b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥251.00
7D
2.0%
1Y
-40.7%
StemRIM
Market Cap: JP¥19.4b
A biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally.
4599
JP¥310.00
7D
-1.0%
1Y
1.3%
Kidswell Bio
Market Cap: JP¥7.6b
Develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan.
4584
JP¥156.00
7D
14.7%
1Y
-32.8%
Noile-Immune Biotech
Market Cap: JP¥5.3b
Researches and develops CAR-T cells for novel cancer immunotherapies.
4893
JP¥128.00
7D
6.7%
1Y
-25.1%
TMS
Market Cap: JP¥5.0b
Engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities.
4891
JP¥108.00
7D
6.9%
1Y
-32.5%